BioSpace News Archive

Salveo Agro and Zentia AG announced that Zentia, a family office’s private holding and investment company, entered as an early investor and for a material stake into Salveo Agro, a new technology-based crop protection and biotechnology company developing natural crop protection products and biostimulants based on their patented Tectus Matrix® technology.

BioAdaptives, Inc. (OTCMkts: BDPT), In reference to the previous Press Release of February 24, 2022, the Company announced today that it will continue providing Pluripain® and monitoring the use of this product by those suffering from the symptoms of Gadolinium Deposition Disease (GDD).

Dentsply Sirona will introduce a series of innovations designed to significantly enhance digital workflows with benefits for dentists, dental labs and patients globally.

Two studies on COVID-19 patients were conducted in Field Hospital No. 3 by Traditional Medicine Institute of Ho Chi Minh City.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.95 per share on its outstanding shares of Common Stock.

DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT (rebonuputemcel).

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression ≥ 1%.

Recommendation based on positive results from the Phase 3 CheckMate -648 trial, in which the combination demonstrated significantly improved overall survival compared to chemotherapy.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 10, 2022 after the close of the financial markets.

Atrion Corporation (NASDAQ: ATRI) today announced its results for the fourth quarter ended December 31, 2021 and the full year 2021.